Gene Editing, Gene Sequencing and In-Vivo - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Editing

Gene Sequencing

In-Vivo

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). It is also working with Eli Lilly on in vivo gene-editing drugs against three targets, including one in Duchenne muscular dystrophy, under the terms of a $1.4

Gene Editing

Gene Editing In-Vivo Gene Sequencing Gene

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . Vertex is also offering up to $1.3

Gene Editing

Gene Editing Genetics Drugs Gene

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

Stay Connected